Botulinum Toxin Injection to Prevent Ventricular Arrhythmias

Endomyocardial Botulinum Toxin Injection Can Prevent Ventricular Arrhythmias: Pilot Study

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02003001

Enrollment

Registered

2013-12-06

Start date

2013-06-30

Completion date

2016-12-31

Last updated

2015-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic Ventricular Asystolia, Ventricular Tachycardia

Brief summary

The aim of this prospective non-randomized study was to assess the efficacy and safety of endomyocardial botulinum toxin injection in left ventricle for preventing ventricular arrhythmias.

Interventions

DRUGBotulinum Toxin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* symptomatic ventricular arrhythmias * drug-resistance * unsuccessful one or more ablation procedure with future unreasonable tries

Exclusion criteria

* Previous heart surgery and AF ablation procedure * Emergency CABG * Unstable angina or heart failure * Use antiarrhythmic drugs within 5 elimination half-lives of the drug (or within 2 months for amiodarone) * Requiring concomitant valve surgery * Left ventricle ejection fraction \<35% * Unwillingness to participate

Design outcomes

Primary

Measure	Time frame
freedom of ventricular arrhythmias	1 year

Secondary

Measure	Time frame
serious adverse events	1 year
time to recurrence of ventricular arrhythmias	1 year

Countries

Russia

Contacts

Primary ContactEvgeny Pokushalov, MD, PhD

e.pokushalov@gmail.com+79139254858

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026